Neurocrine Biosciences (NBIX): Buy Ahead Of valbenazine Tourette’s Data - BMO

October 13, 2016 7:12 AM EDT
Get Alerts NBIX Hot Sheet
Price: $43.79 -2.21%

Rating Summary:
    16 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 45 | New: 20
Trade NBIX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Neurocrine Bio. (NASDAQ: NBIX) seeing the recent price weakness as a buying opportunity. NBIX has come under pressure following Myovant's S-1 filing as investors viewed relugolix as a more convenient competitor to Neurocrine’s elagolix.

The analyst sees two key risks with relugolix: its longer half-life could complicate add-back therapy and endometriosis endpoint wording could delay P3s. Additionally, relugolix endometriosis data suggests a profile similar to lower dose of elagolix and regulatory timelines that provide elagolix a 2-3yr lead-time with peak market share assumptions leaving plenty of room for both players.

The analyst thinks the weakness is a buying opportunity and recommends buying NBIX ahead of P2 valbenazine Tourette’s data in 4Q16.

No change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $43.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital, S1

Add Your Comment